Greenland Mines (GRML) Stock Overview
Develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GRML Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Greenland Mines Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$3.91 |
| 52 Week Low | US$0.11 |
| Beta | 2.23 |
| 1 Month Change | 77.84% |
| 3 Month Change | 2.42% |
| 1 Year Change | 44.71% |
| 3 Year Change | -96.00% |
| 5 Year Change | n/a |
| Change since IPO | -95.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRML | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.6% | -0.6% | -2.3% |
| 1Y | 44.7% | 25.1% | 20.4% |
Return vs Industry: GRML exceeded the US Biotechs industry which returned 25.1% over the past year.
Return vs Market: GRML exceeded the US Market which returned 20.4% over the past year.
Price Volatility
| GRML volatility | |
|---|---|
| GRML Average Weekly Movement | 25.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GRML's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRML's weekly volatility has decreased from 115% to 25% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Joe Sinkule | greenlandmines.com |
Greenland Mines Ltd develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026.
Greenland Mines Ltd Fundamentals Summary
| GRML fundamental statistics | |
|---|---|
| Market cap | US$50.59m |
| Earnings (TTM) | -US$11.29m |
| Revenue (TTM) | n/a |
Is GRML overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRML income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.29m |
| Earnings | -US$11.29m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GRML perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 02:31 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Greenland Mines Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.